Skip to main content
Sign In
 

Christine M. Fisher Publications


Publications:

  1. Fisher, CM, Troncoso P, Kuban DA, Munsell M, Yeh S, Lee AK, Swanson DA, Frank SJ.   (2012).  Knife or needles?  A cohort analysis of low and intermediate risk men treated definitively for adenocarcinoma of the prostate. Accepted, Brachytherapy.
  2. Fisher, CM, Jhingran, A, Fortenberry, B, Eifel, PJ.  (2011).  A novel technique for the simulation and treatment planning of obese patients.  Practical Radiation Oncology, July 1(3): 152-155.
  3. Phan, J, Mazloom, A, Abboud, M, Salehpour, M, Reed, VK, Zreik, T, Shihadeh, F, Fisher, CM, Wogan, C, Dabaja, BS.  (2011).  Consolidative Radiation Therapy for Stage III Hodgkin Lymphoma in Patients Who Achieve Complete Response After ABVD Chemotherapy.  American Journal of Clinical Oncology, Accepted, published online..   
  4. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher CM, Shriver CD, Ioannides CG, Ponniah S. (2005).  Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients.  Journal of Clinical Oncology,Oct 20;23(30):7536-45. 
  5. Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher CM, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.  (2005). Phase I clinical trial of a HER2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.  Clinical Cancer Research, Oct 15;11(20):7470-9. 
  6. Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. (2004). Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the In Vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.  Journal of Clinical Immunology, Jul;24(4):449-61.